Inflammatory Cytokines in Diabetic Kidney Disease: Pathophysiologic and Therapeutic Implications

被引:71
作者
Donate-Correa, Javier [1 ,2 ]
Ferri, Carla M. [1 ,3 ]
Sanchez-Quintana, Fatima [1 ,3 ]
Perez-Castro, Atteneri [1 ]
Gonzalez-Luis, Ainhoa [1 ]
Martin-Nunez, Ernesto [1 ,2 ,3 ]
Mora-Fernandez, Carmen [1 ]
Navarro-Gonzalez, Juan F. [1 ,2 ,4 ,5 ]
机构
[1] Hosp Univ Nuestra Senora Candelaria, Unidad Invest, Santa Cruz de Tenerife, Spain
[2] Soc Espanola Nefrol, GEENDIAB Grp Espanol Estudio Nefropatia Diabet, Santander, Spain
[3] Univ La Laguna, Doctoral & Grad Sch, San Cristobal De La Lagu, Spain
[4] Inst Salud Carlos III, REDINREN Red Invest Renal RD16 0009 0022, Madrid, Spain
[5] Univ La Laguna, Inst Tecnol Biomed, Santa Cruz De Tenerife, Spain
关键词
diabetic kidney disease; inflammation; inflammatory cytokines; SGLT2i; GLP-1RA; DPP-4i; pentoxifylline; TUMOR-NECROSIS-FACTOR; NF-KAPPA-B; URINARY PROTEIN EXCRETION; ISOLATED RAT GLOMERULI; TNF-ALPHA; ANGIOTENSIN-II; IFN-GAMMA; PROSTAGLANDIN PRODUCTION; DIPEPTIDYL PEPTIDASE-4; TH17; DIFFERENTIATION;
D O I
10.3389/fmed.2020.628289
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Diabetic kidney disease (DKD) is the leading cause of end-stage renal disease and a main contributing factor for cardiovascular morbidity and mortality in patients with diabetes mellitus. Strategies employed to delay the progression of this pathology focus on the control of traditional risk factors, such as hyperglycemia, and elevated blood pressure. Although the intimate mechanisms involved in the onset and progression of DKD remain incompletely understood, inflammation is currently recognized as one of the main underlying processes. Untangling the mechanisms involved in the appearing of a harmful inflammatory response in the diabetic patient is crucial for the development of new therapeutic strategies. In this review, we focus on the inflammation-related pathogenic mechanisms involved in DKD and in the therapeutic utility of new anti-inflammatory strategies.
引用
收藏
页数:9
相关论文
共 123 条
[1]   The anti-inflammatory effects of the phosphodiesterase inhibitor pentoxifylline in the rat [J].
Abdel-Salam, OME ;
Baiuomy, AR ;
El-Shenawy, SM ;
Arbid, MS .
PHARMACOLOGICAL RESEARCH, 2003, 47 (04) :331-340
[2]   Comparison of the effect of pentoxifylline and captopril on proteinuria in patients with type 2 diabetes mellitus [J].
Aminorroaya, A ;
Janghorbani, M ;
Rezvanian, H ;
Aminian, T ;
Gharavi, M ;
Amini, M .
NEPHRON CLINICAL PRACTICE, 2005, 99 (03) :C73-C77
[3]   Predictive impact of elevated serum level of IL-18 for early renal dysfunction in type 2 diabetes: an observational follow-up study [J].
Araki, S. ;
Haneda, M. ;
Koya, D. ;
Sugimoto, T. ;
Isshiki, K. ;
Chin-Kanasaki, M. ;
Uzu, T. ;
Kashiwagi, A. .
DIABETOLOGIA, 2007, 50 (04) :867-873
[4]   The epidemiology of chronic kidney disease [J].
Atkins, RC .
KIDNEY INTERNATIONAL, 2005, 67 :S14-S18
[5]   Decreased carotid atherosclerotic process by control of daily acute glucose fluctuations in diabetic patients treated by DPP-IV inhibitors [J].
Barbieri, M. ;
Rizzo, M. R. ;
Marfella, R. ;
Boccardi, V. ;
Esposito, A. ;
Pansini, A. ;
Paolisso, G. .
ATHEROSCLEROSIS, 2013, 227 (02) :349-354
[6]   TUMOR NECROSIS FACTOR STIMULATES PROSTAGLANDIN PRODUCTION AND CYCLIC-AMP LEVELS IN RAT CULTURED MESANGIAL CELLS [J].
BAUD, L ;
PEREZ, J ;
FRIEDLANDER, G ;
ARDAILLOU, R .
FEBS LETTERS, 1988, 239 (01) :50-54
[7]   NF-κB in Renal Inflammation [J].
Belen Sanz, Ana ;
Dolores Sanchez-Nino, Maria ;
Mario Ramos, Adrian ;
Antonio Moreno, Juan ;
Santamaria, Beatriz ;
Ruiz-Ortega, Marta ;
Egido, Jesus ;
Ortiz, Alberto .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2010, 21 (08) :1254-1262
[8]  
BERTANI T, 1989, AM J PATHOL, V134, P419
[9]  
Blagosklonnaia Ia V, 1982, Probl Endokrinol (Mosk), V28, P3
[10]   Tumor necrosis factor-α promotes macrophage-induced vascular smooth muscle cell apoptosis by direct and autocrine mechanisms [J].
Boyle, JJ ;
Weissberg, PL ;
Bennett, MR .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2003, 23 (09) :1553-1558